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Abstract
The following is the summary report on the UHMS Pacific Chapter Annual Meeting held in Long Beach in October
2010. The conference provided the latest updates on scientific, technical and organizational aspects of Hyperbaric
and Diving Medicine. Invited speakers gave series of lectures dealing with current standards of clinical practice and
presenting the results of laboratory investigations with particular emphasis on mechanisms of hyperbaric oxygen
therapy. Scientific sessions were accompanied by vendor exhibits and social events.
Introduction
Many hyperbaric medicine practitioners, research scien-
tists and health care providers attended the Pacific
Chapter Annual Meeting of the Undersea and Hyperba-
ric Medical Society held in Long Beach California
between October 15 and 17 (Friday through Sunday) in
2010. In the splendid interior of Hyatt Regency took
p l a c eav e r yi n f o r m a t i v ec o n f erence updating partici-
pants on the latest developments yet building on well
established concepts in the field.
The 2010 annual meeting was chaired by the President
of UHMS Pacific Chapter Dr. Stuart Miller, hyperbaric
medicine specialist from Long Beach Memorial, and an
expert in wound care.
There were several accompanying events and attrac-
tions including exhibits, a lottery with tickets to the
Aquarium of the Pacific and hyperbaric medicine books
as prizes, and UHMS Pacific Chapter Executive Com-
mittee Meeting.
It was a good meeting that helped to span the gap
between basic sciences and hyperbaric medicine prac-
tice. The meeting offered also in depth insight on new
applications of hyperbaric oxygen and the mechanisms
of treatment. Those three memorable days at Long
Beach were filled with exchange of opinions, vigorous
discussions and social activities. The presented material
could be classed into the following categories: 1) exposi-
tory lectures on hyperbaric medicine applications in
diving and in different medical conditions including
wound care, osteomyelitis, plastic surgery problems,
cardiovascular diseases, and organ transplant, all inter-
twined with basic science data and the overview of
experimental and clinical studies; 2) case presentations
with literature review; 3) health insurance issues with
regard to HBO treatment, the logistics of hyperbaric
medicine procedures and specialty information.
Hyperbaric Medicine Lectures
On Friday, hyperbaric medicine lectures began with an
interesting presentation by Dr. Karen Van Hosen from
UCSD. She gave an overview of multiple factors that
determine physiological phenomena and treatment out-
comes in decompression sickness. Those included nitric
oxide, heat shock proteins, cold stress and genetic
susceptibility.
On the very same day came out an interesting presenta-
tion on medications in diving provided by Dr. Nicholas
Bird, chief medical officer of Divers Alert Network.
Dr. Bird laid out physician’s views on evaluation of divers
who take medications. The safety of diving on meds
remains an issue somewhat unresolved. Many medications
have been found unconnected to diving risks, however
medications as markers of chronic conditions surely indi-
cate that diver’s fitness to dive may be compromised [1].
Special concerns have been voiced over sedatives and
anxiolytics as well as narcotic pain medications. These
meds can impair the performance of the diver by impair-
ing physical fitness/exercise capacity or mental status.
On Saturday Dr. Garret Wirth gave a talk on hyperba-
ric oxygen therapy in plastic and reconstructive surgery.
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Memorial and a plastic surgeon at UCI. After presenta-
tion of graphic images of bodily defects and mutilations
seen by reconstructive surgeons in their practice,
Dr. Wirth evoked a description of Dantes’ 8th circle of
hell and physical deformities sustained by its inhabitants.
The presentation was further unfolded to offer an over-
view of plastic/reconstructive surgery techniques and
HBO applications for improving survival of flaps and
grafts [2]. As it was stressed normal flaps or grafts with
uncompromised blood supply do not require HBO how-
ever this modality should be used when there is a docu-
mented perfusion concern or vascular insult [3]. In
addition this treatment is usually done after surgical
measures have been considered. The animal studies and
clinical reports have also shown that HBO increases the
length of vessel growth in pedicled flaps [3,4]. Dr. Wirth
offered examples of how he uses HBO in his practice of
plastic and reconstructive surgery. Flap deterioration,
compromised replants, wounds in the irradiated fields,
wounds with polymicrobial infections and after crush
injury comprised the majority of presented indications.
He also pointed out that the use of HBO for cosmetic
surgery has been recently compromised by bad economy.
The following was hyperbaric literature update pre-
sented by Dr. Dick Clarke. He began his informative talk
with discussing a report on facilitated chronic foot ulcers
healing in the diabetic patients with HBO therapy [5].
Dr. Clarke outlined the criteria of enrollment and rando-
mization and presented the outcomes. This noteworthy
study, published in Diabetes Care, adopted a double
blinded design and followed the rules of randomization.
Londahl and collaborators were able to evidence signifi-
cantly improved indexes of foot healing in the HBO
group over placebo. Study design, as pointed out by
Dr. Clarke, adheres to CONSORT criteria [6]. Dr. Clarke
was able to identify only a few insufficiencies of the study
including the lack of transcutaneous oximetry monitoring
in the course of therapy [7]. However, he also presented
the counterpoint to findings favorable for HBO, pub-
lished as an editorial by Dr. Berendt in Clinical Infectious
Diseases [8]. According to Dr. Berendt’s view the evi-
dence is not strong enough to conclude that HBO is
effective in the treatment of chronic foot ulcers in dia-
b e t i cp a t i e n t s .O n eo ft h em a j o rg o a l so fH B Ot h e r a p yi s
to avoid amputation in such patients. The study by
Londahl did not show clinical benefit with this regard
however other authors reported that amputation rate
decreased in HBO treated patients [9,10]. Dr. Clarke
postulated that conducting large controlled randomized
double blinded trials should be done before consensus
can be reached on this issue. Dr. Clarke further stressed
the need to monitor tissue oxygen concentration in
patient undergoing HBOT. The rise in tissue oxygen
pressure may be insufficient in patients undergoing HBO
therapy and this inadequate response can lead to healing
failure. Moreover low pt O2 v a l u e si nt h ec o u r s eo ft h e r -
apy allow to predict which wounds will not heal [11,12].
Next, Dr. Clarke discussed the latest literatures on the
use of HBO in the necrotizing soft tissue infections
(NSTI). A recent study has demonstrated that HBO did
not show clinical benefits in NSTI despite aggressive
treatment regimen (consistent with the treatment of gas
gangrene) [13]. In another discussed paper, however,
Hassan and coworkers from Burn Center at Augusta
found a strong tendency towards reducing amputation in
patients with necrotizing fasciitis treated with HBO [14].
Dr. Clarke also presented the results of clinical investiga-
tions that revealed improved quality of life in patients
treated with HBO after radiation of head and neck
tumors. The treatment regimen comprised 30 sessions of
hyperbaric oxygen at 2.5 ATA. The total radiation dose
received by patients in that study was 46 Gy over 15
days, which is significant [15]. Dr. Clarke pointed out
that the study was underpowered and lacked blinded pro-
tocol. He also raised ethical concern over quality of life in
the untreated controls as an outcome and over patients’
consent to suffering. Other studies dealing with HBOT
for osteoradionecrosis (ORN) seem to provide conflicting
results. For example the data published by Dr. Annane’s
group in 2009 do not seem to build a strong case for
HBO use in ORN [16,17]. Dr. Clarke discussed several
factors that could weigh in on the quality of this study
and authors’ conclusions. Although most studies suggest
beneficial role of HBO in ORN, further research is
needed to validate use of HBO against radiation induced
injuries [18-20]. Then the audience was updated on HBO
administration in cardiovascular diseases. Dr. Yogarat-
nam and colleagues preconditioned patients with HBO
for two 30-minute intervals at 5 minutes apart on the
morning of coronary artery bypass grafting (CABG) [21].
HBO preconditioning (HBO PC) improved left ventricu-
lar stroke work in these patients and decreased their
length of stay in ICU. In addition, smaller rise in serum
troponin level was noted in HBO PC group. The authors
advocated larger trial with improved scientific rigor.
Dr. Clarke praised promising results of this study and
recalled earlier reports from this group successfully using
HBO PC for patients awaiting CABG with cardio pul-
monary bypass [22].
Next presentation, done by Dr. Robert Ostrowski from
Loma Linda University detailed the effect of hyperbaric
oxygen treatment on neural tissue. He reviewed basic
research that has been done in the past couple of years.
The large portion of results originated in the lab of
D r .J o h nZ h a n gw h oi saw o r l dr e n o w n e de x p e r ti n
experimental hyperbaric medicine. Dr. Ostrowski
emphasized superiority of hyperbaric oxygen over
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models of stroke. Part of the presentation was dealing
with recent discoveries of molecular pathways that
underlie HBOT action. New treatment strategies that
combine HBO with pharmacological agents (including
JNK inhibitors) to increase neuroprotective effect were
o n eo fm a n yi s s u e sa t t r a c t i n ga u d i e n c ea t t e n t i o n[ 2 3 ] .
Experimental studies on surgical brain injury and global
cerebral ischemia ascribed increasing role in mediating
HBO mechanisms preconditioning (HBO-PC) to cycloox-
ygenase 2 (COX-2) [24,25]. Another candidate mechanism
of HBOT preconditioning postulates the exhaustion of the
extracellular proteolysis [26]. Dr. Ostrowski also cited
recent finding revealing that HBO can induce expression
of nuclear factor E2-related factor-2 (Nrf2), which is a key
regulator in reducing oxidative stress, inflammation and
accumulation of toxic metabolites in cerebral tissues [27].
However, further studies are needed to address to what
extent newly implicated pathways are involved in HBO
mechanisms. Undergoing studies also point towards an
important role of HBO in the activation of neurogenesis,
which carries significant clinical potential for regeneration
of the brain after major stroke associated with tissue loss
[28-30]. During discussion that followed some participants
raised concerns over short regimens of experimental HBO
treatment that might not be intensive enough to provide
significant improvement in the clinical setting. The discus-
sion also touched upon theoretical foundations of HBO
combined with pharmacological agents or with other pre-
conditioning modalities such as hypothermia [31] followed
by questions of optimal timing for combined treatment in
the clinical setting.
During another interesting presentation Dr. Ostrowski
laid out historical background and summarized recent
advancements in the use of HBO for organ transplant.
HBO have been used in a variety of clinical and experi-
mental transplantation procedures involving intestine,
pancreas and liver [32-35]. HBOT was found to improve
graft survivability and function in the experimental set-
ting [36]. Laboratory investigations revealed several
mechanisms of how HBO benefits transplanted organs
including disruption of hypoxic signaling reflected by a
decreased level of hypoxia inducible factor 1 a,a sf o u n d
in transplanted syngeneic pancreatic islets [37].
Dr. Ostrowski reviewed progress in the use of HBOT for
preservation of organ transplants including HBO pre-
treatment of donors [38]. In the discussion that ensued
hyperbaric medicine practitioners pointed out that HBO
researchers need to further address usefulness of HBO
treatment for allogenic transplants. Dr. Stuart Miller
suggested testing the impact of HBO on the transplant
triggered immunologic response and HBO interactions
with immunosuppressants commonly administered to
transplant recipients.
Then Dr. Michael Strauss from Long Beach Memorial
took the floor with arch interesting lecture dealing with
refractory osteomyelitis. He presented definition and
pathophysiology of osteomyelitis, the inflammation of the
bone and bone marrow, with clinical presentations and
HBO treatment protocols. More than ever HBO is used
for refractory osteomyelitis [39]. As one of the major
mechanisms of HBOT in osteomyelitis Dr. Strauss indi-
cated increased intramedullary oxygen tension to the
point where killing microbial organisms by WBC becomes
effective. Earlier studies have shown that HBO in osteo-
myelitis was as effective as cephalexin however there was
no additional benefit from HBO/antibiotic combo [40].
Moreover, HBO is bactericidal, and has been also shown
to stimulate osteoclasis and angiogenesis [41]. More
importantly HBO therapy produces good outcomes in
over 80 percent of patients with osteomyelitis [42].
Dr. Strauss also evaluated clinical tests for diagnosing
osteoradiomyelitis and suggested cautious interpretation
of MRI which can give 50% false positives. Finally, he
addressed academic integrity issues, which might affect
the quality of results in some studies in this field.
Dr. Strauss continued lecturing on Sunday by outlining
“reasons problem wounds fail to heal”. According to
Dr. Strauss, diabetic foot wound healing is compromised
by a triad of factors formed by unresolved infection,
hypoxia, and deformities. Dr Strauss addressed clinical
management of all these conditions including use of HBO
with aid of illustrations and clinical documentation. HBO
ameliorates healing through several factors, including
reduced edema in the wound, increased blood oxygen
content and improved oxygen diffusion [43,44]. HBO-
induced blood hyperoxygenation more than compensates
reduced flow from vasoconstriction [45]. Dr. Strauss also
pointed out that HBO drastically reduced amputation
rates in a presented group of patients.
Case Presentations
Series of interesting case presentations were given by
Drs. Jeff Sipsy, Tom Ascuito, and Enoch Huang on Fri-
d a ya n do nt h ef o l l o w i n gd a yb yD r s .S u s a nS p r a u ,
Ralph Potkin and Roxanna Sadri.
Friday case presentations included Dr. Enoh Huang’s
talk revealing the history of 68 old woman with TRAM
flap applied after lateral mastectomy. The patient condi-
tion was deteriorating as the flap, showing skin color
changes, was dying. The patient received a total of 20
dives at 2 ATA of 90 minute duration (BID). The photo-
graphic documentation confirmed that the flap showed
remarkable amelioration under HBO treatment. Dr.
Huang discussed mechanisms of HBO therapy for flap
survival including the inhibition of leukocyte endothelial
intravascular adhesion and direct oxygenation of ischemic
tissues by increasing oxygen dissolved in plasma. In this
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tion is occluded to the point that RBC cannot pass
through capillaries [46].
On the following day Dr. Susan Sprau from UCLA
shared her experience from treating the acute postsurgical
optic neuropathy. The patient, 29 yr old male, presented
with cystic mass in the left orbit that was later diagnosed
as schwannoma. The tumor was surgically removed.
Patient’s vision deteriorated after surgery from normal
acuity to merely light perception, however. Optic nerve
edema was present on physical exam. The patient was
treated with steroids and HBOT modified navy TT5 then
TT9 [47]. During the initial several days of treatment,
vision improved at depth and deteriorated at the surface.
Total number of HBOTs was 19, administered over
12 days. This treatment resulted in amelioration of swel-
ling and improved visual acuity 20/25 with normal color
testing. Dr. Sprau concluded that vision loss after ophthal-
mologic surgery may favorably respond to HBOT [48].
In turn Drs. Roxana Sadri and Emi Latham from UCSD
hyperbaric medicine center presented a case of iatrogenic
embolism. 58 yr old woman with myofascial pain syn-
drome, paresthesia and the paralysis in the right arm and
leg after radiofrequency thermoablation was initially trea-
ted with USN TT6 followed by Table nine on day 3,4 and
5 [49]. The authors noted significant sensory and motor
improvement in the patient although the residual deficit
forced her to walk with a cane. Dr. Sadri also discussed
two cases of intramedullary gas bubbles secondary to epi-
dural injections. She summarized routes of gas invasion
and clinical treatment regimens [50].
Logistic, Occupational, and Health Insurance
Aspects in Hyperbaric and Diving Medicine
Several UHMS meeting presentations were dealing with
logistic of running HBO facilities, health insurance
requirements for reimbursing HBO therapy as well the
education of hyperbaric medicine practitioners. On the
first day of the conference Dr. Enoh Huang was talking on
hyperbaric medicine subspecialty and gave us an update
on hyperbaric medicine fellowships. Also on that day
Dr. Nicolas Bird provided a presentation on Divers Alert
Network (DAN). It is a very useful enterprise, with fre-
quently updated website providing industrial and indivi-
dual divers with tangible information. DAN promotes
research activity to investigate questions regarding health
and safety of divers. Quite recently Dr. Nicholas Bird filled
its full-time chief medical officer position to oversee net-
work’s mission. One of the ongoing projects there investi-
gates potential seizure threshold lowering effect of sudafed
in the HBO environment [51]. This study, being con-
ducted in collaboration with Dr. Jay Dean as a PI was
launched in 2010 at the University of Florida. The aim of
another ongoing study is to compare diving performance
of the individuals with patent foramen ovale (PFO) versus
those with medically closed foramen ovale. The foramen
ovale situated in the interatrial septum allows blood to
circumvent pulmonary circulation in utero [52]. The clo-
sure of foramen ovale is not complete in 25% adults hence
its significant prevalence amongst divers. PFO is not a
threatening condition in the general population however
in divers it can pose a risk of an arterial gas embolism in
decompression illness (gas bubbles pass directly into the
left atrium bypassing the lungs). DAN investigators are
currently working to establish the criteria for closing fora-
men ovale that would take into account past history of
decompression sickness (DCS), presence of IE or neurolo-
gical DCS, size of foramen ovale and required level of
diver’s performance. DAN website offers an interesting
selection of diving medicine articles: http://www.diversa-
lertnetwork.org. Dr. Bird also discussed needs of veteran
members of DAN. With the help from epidemiology PhD
students, the complete survey of divers is underway. It is
“aimed at establishing the prevalence of cardiovascular
risk factors, diabetes, asthma, access to health care and
diving practice”. Interestingly, divers appear to have less
chronic symptomatic diseases than in the general popula-
tion. DAN investigators also pointed out that age itself is
not a causative factor for death in known diving accidents
and identified major triggers of death as insufficient gas,
entrapment and equipment problems [53].
Also on the first day of the meeting Dr. Karen Van
Hosen gave a talk on how to establish diving medicine
clinic and evaluate recreational, scientific and commer-
cial divers for clearance to dive.
Another Friday talk provided an overview of diving com-
puter applications. It was presented by Dr. Karl Huggins
from Catalina hyperbaric chamber at the University of
Southern California. Dr. Huggins covered the basics then
moved on to specify what data are collected by diving
computes (depths, times, warnings, decompression status,
temperatures and dive profiles) and delineated data acqui-
sition modes [54]. This was followed by examples of dive
computer recordings and their interpretation, including
analysis of data recovered from fatalities.
The hyperbaric medicine practice and coding formed
the title of presentation provided by Dr. Dick Clarke on
Saturday. In the course of his talk Dr. Clarke laid out the
strategy of how to handle HBO treatments for reimburse-
ment purposes. One of ways of dealing with this issue is to
seek pre-authorization to treat. Unfortunately some
insurers specifically indicate that use of HBO is not reim-
bursable for prophylactics of certain conditions such as
mandible osteoradionecrosis. Dr. Clarke provided the
points that can bolster argumentation that use of HBO is
medically necessary [55]. Interesting presentation was also
delivered by Dr. Ralph Potkin who shared his experience
from work at the free-standing HBO facility. Dr. Potkin
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tic insight on managing the facility.
With great interest the audience welcomed a Sunday
presentation given by Dr. Kim Buschmann from the Cana-
dian Navy who is also an instructor of hyperbaric medi-
cine at UCSB. She presented tasks, risks and problems
experienced by technical divers including nitrogen narco-
sis. Dr. Buschmann offered an overview of decompression
schedules. The presentation gave everyone quite an insight
into respiratory physiology of diving addressing issues
such as work of breathing and impact of increased density
of gas on respiratory dead space, and the effects of hyper-
capnia, hyperoxia and hypoxia on respiratory physiology
parameters [56]. Dr. Buschmann also addressed problems
of inner ear decompression including selection of decom-
pression gasses for treatment [57,58].
An interesting lecture on hyperbaric oxygen chamber
safety in a large urban healthcare facility was given by
Dr. David Stiles. Dr. Stiles briefly presented the history
of Long Beach Memorial opened in 1907 as Seaside
Hospital. Its Hyperbaric Medicine Department has 6
monoplace treatment chambers and in its 30 year his-
tory treated 20,000 plus patients. Dr. Stiles provided an
overview of procedures at hyperbaric facility, identified
prospective areas of innovation, and addressed problems
that may arise during standard operating procedures.
This presentation was followed by Dr. John Kades’ talk,
focusing on the guidelines of forensic investigations of
diver deaths.
Future Studies and Conclusions
Presentation of many novelties and often highly experi-
mental approaches frequently led to controversy that
stirred vivid discussion on the future directions for
hyperbaric medicine. Certain case reports raised criti-
cism of other hyperbaric medicine practitioners over too
conservative treatment. During the meeting, several par-
ticipants were trying to work out the consensus between
basic science results and clinical practice in hyperbaric
medicine. They stressed the existing gap between these
two fields and postulated to increase translatability of
laboratory investigations. In particular Dr. Miller
addressed the paucity of results on several important
molecular and cellular aspects of HBOT in organ trans-
plant studies and in wound care research. Participants
discussed the use of HBOT in combination with phar-
macological agents and personalized treatment regi-
mens. The need to develop new molecular markers for
monitoring effects of HBO therapy also emanated from
the discussion. Many participants postulated to increase
scientific rigor of experimental and clinical studies with
HBOT for improved quality of results and academic
excellence.
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